Good afternoon :)
$
₹
Eli Lilly and Company

Eli Lilly and Company

LLY

NYSE
Asset Logo

Eli Lilly and Company

LLY

NYSE
$1,188.671.60% (+18.81)
$
₹
$1,188.671.60% (+18.81)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Drug Manufacturers - General

Mega Cap

With a market cap of $1.0T the stock is ranked 15

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

41.55
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

31.88
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$28.15
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

1.55
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

34.99%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

0.55%

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 31 analysts' reports

Buy
24 analysts
Hold
5 analysts
Sell
2 analysts

Analysts expect a +7.13% price upside over the next year

Current Price$1,188.67
Target Price$1,276.96

Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Peers

Peers

Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
29.57
29.57
1Y Return
52.71%
52.71%
Buy Reco %
45.83
45.83
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
101.84
101.84
1Y Return
63.18%
63.18%
Buy Reco %
57.69
57.69
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
23.32
23.32
1Y Return
35.86%
35.86%
Buy Reco %
15.38
15.38
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
23.30
23.30
1Y Return
9.46%
9.46%
Buy Reco %
90.00
90.00
Novo Nordisk A/S
NVO
Novo Nordisk A/S
P/E Ratio
10.96
10.96
1Y Return
2.44%
2.44%
Buy Reco %
41.66
41.66

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - General

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Eli Lilly and Company 41.5531.881.55
Johnson & Johnson29.577.234.20
Merck & Company Inc101.846.8911.85

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

17.6
5.5
19.2
6.6
19.7
7.3
22.9
7
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue8.7611.3011.4313.5312.7215.5517.6019.2919.7922.97
Net Income2.242.960.974.402.755.665.586.637.397.09
Net Profit Margin25.58%26.25%8.48%32.58%21.67%36.38%31.71%34.39%37.35%30.88%
See CostsAll values in $ Billion

Frequently asked questions

Frequently asked questions

  1. What is Eli Lilly and Company's share price today?

    Eli Lilly and Company (LLY) share price today is $1,188.67 as of August 7, 2026 at 12:44 AM IST. The stock touched a day high of $1,227.75 and a day low of $1,173.91.

  2. What exchange does Eli Lilly and Company stock trade on, and under what ticker symbol?

    Eli Lilly and Company stock trades on NYSE under the ticker symbol LLY.

  3. What is Eli Lilly and Company's market capitalization?

    Eli Lilly and Company's market capitalization is $1.04M as of August 7, 2026 at 12:44 AM IST.

  4. What is Eli Lilly and Company's price-to-earnings (P/E) ratio?

    Eli Lilly and Company's price-to-earnings (P/E) ratio is 41.55 as of August 7, 2026.

  5. What is Eli Lilly and Company's price-to-book (P/B) ratio?

    Eli Lilly and Company's price-to-book (P/B) ratio is 31.88 as of August 7, 2026.

  6. Does Eli Lilly and Company pay a dividend, and what is its dividend yield?

    Yes, Eli Lilly and Company pays a dividend, with a current dividend yield of 0.55%.

  7. Can Indian investors buy Eli Lilly and Company shares?

    Yes, Indian residents can invest in Eli Lilly and Company shares by opening a US brokerage account through a SEBI-compliant platform, subject to RBI's Liberalised Remittance Scheme (LRS) limits.

  8. How can I invest in Eli Lilly and Company shares from India?

    Indian investors can buy Eli Lilly and Company shares in three steps: open a US brokerage account through a SEBI-compliant platform, complete the digital KYC process, and transfer funds under the RBI's Liberalised Remittance Scheme (LRS) to start investing.

  9. How does USD-INR currency movement affect returns from Eli Lilly and Company shares for Indian investors?

    Since Eli Lilly and Company trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

Loading...